Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 14/20 | 0.40 |
| ▸ | DRD2 | P14416 | 8/20 | 0.38 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21353788 | 0.82 | TNKS (0.44) | TNKSDRD3DRD2 | |
| SCHEMBL22079488 | 0.75 | DRD3 (0.40) | TNKSDRD3DRD2HPGD | |
| SCHEMBL2011238 | 0.75 | KDM4E (0.46) | TNKSHPGD | |
| SCHEMBL543378 | 0.75 | NR4A2 (0.45) | TNKS | |
| SCHEMBL22723833 | 0.74 | SYK (0.44) | TNKS | |
| SCHEMBL28910011 | 0.74 | KDM4E (0.44) | TNKSDRD3HPGD | |
| Potassium Ion SCHEMBL23858799 | 0.73 | TNKS (0.39) | TNKSDRD3DRD2HPGD | |
| SCHEMBL19903055 | 0.72 | TNKS (0.38) | TNKSDRD3DRD2 | |
| SCHEMBL30969206 | 0.71 | KEAP1 (0.43) | HPGD | |
| SCHEMBL22722201 | 0.71 | HDAC8 (0.59) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495363-B1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | TNKS 4753/4885DRD3 1/4885DRD2 3/4885 |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | TNKS 4753/4885DRD3 1/4885DRD2 3/4885 |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | TNKS 4753/4885DRD3 1/4885DRD2 3/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | TNKS 4753/4885DRD3 1/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.